Medicare utilization — ANGELA EMERSON (PA-C)
Calendar year 2023 · data refreshed 2026-05-27
| HCPCS | Description | Services | Beneficiaries | Allowed | Payment |
|---|---|---|---|---|---|
| J1453 | Injection, fosaprepitant, 1 mg | 15,000 | 43 | $0 | $1,872 |
| J9263 | Injection, oxaliplatin, 0.5 mg | 11,600 | 11 | $0 | $658 |
| J9271 | Injection, pembrolizumab, 1 mg | 7,000 | 17 | $0 | $275,091 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 1,794 | 58 | $0 | $172 |
| J1626 | Injection, granisetron hydrochloride, 100 mcg | 1,210 | 32 | $0 | $350 |
Service volume and Medicare payment amounts do not indicate quality of care, patient outcomes, or fraud. Data reflects Medicare fee-for-service only.
Source: CMS public data · Not endorsed by CMS · Beneficiary counts under 11 are suppressed in source data ·